NVCT Stock — Nuvectis Pharma Inc

Nuvectis Pharma Inc (NVCT)

Updated October 16, 2026.

NVCT is a Stock. Total return is 472.3% over the past 4.7 years, 391.1 points ahead of SPY at 81.2%.

Nuvectis Pharma is a clinical-stage biopharmaceutical company developing precision medicines for oncology, with a focus on NXP900, a small molecule drug candidate in Phase 1b trials targeting solid tumors through inhibition of c-Src and YES1 kinases. The company does not currently distribute to shareholders. This security appeals to investors with high risk tolerance seeking exposure to early-stage drug development in oncology, rather than those pursuing current income.

NVCT performance versus SPY

Price and return data through 2026-10-16.

Total return is 472.3% over the past 4.7 years, 391.1 points ahead of SPY at 81.2%. Over the past year its total return — price change plus distributions reinvested — is 205.4%. Its deepest 1-year drawdown was 36.9%.

NVCT key facts

Asset type

Stock

Asset class

Equity

Inception date

02/04/2022

Distribution frequency

None

Last close

$18.60 (as of 2026-10-16)

Market cap

$607,179,628

Average volume

158421.0

Beta

-0.242

Payout ratio

0.0%

EPS

$-1.31

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

NVCT risks and drawbacks

The deepest 1-year drawdown on record here is 36.9%.

Who may consider NVCT — and who may not

It is a weaker fit for investors who need monthly cash flow (NVCT does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on NVCT

• All tickers starting with N

Tagged: Healthcare.

Frequently asked questions